12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Masitinib: Phase III started

AB Science began an open-label, international Phase III trial to compare 7.5 mg/kg/day masitinib vs. dacarbazine in about...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >